What is an accelerated share repurchase (ASR) and why did McKesson use it?

An ASR is a structured transaction in which a company buys a large block of its own shares from an investment bank upfront, with final settlement occurring weeks or months later. McKesson used the ASR mechanism to efficiently execute $2.25 billion of repurchases in May 2026, enabling rapid deployment of capital without prolonging the buyback over many months under standard Rule 10b-18 open-market purchases.

How much did McKesson repurchase in total during Q1 FY27?

McKesson repurchased $2.5 billion of common stock, consisting of $2.25 billion under the May 2026 ASR and approximately $250 million through other means (likely open-market purchases). This was part of a broader $2.6 billion shareholder return that also included $102 million in dividend payments.

Did the buyback materially affect McKesson's earnings per share in Q1?

Yes. Adjusted EPS grew 20% to $9.93 in Q1 FY27 from $8.26 in the prior year. The filing explicitly states that this growth was 'driven by strong operational growth, led by the North American Pharmaceutical and Oncology & Multispecialty segments, and a lower share count,' indicating the 5% year-over-year reduction in diluted shares contributed directly to the EPS accretion.

What is the authorization amount and remaining capacity for this buyback program?

The filing does not disclose the authorization amount or remaining authorization capacity. This is a quarterly earnings release reporting on share repurchases already executed, not an announcement of a new or amended buyback program authorization.

What was the average price paid per share in the Q1 repurchases?

The filing does not disclose the average price paid per share for either the ASR or the total $2.5 billion in repurchases. Only the aggregate dollar amount and the mechanism (ASR plus other repurchases) are specified in the earnings release.

How does McKesson prioritize buybacks relative to other capital allocation?

McKesson states it follows a 'disciplined capital allocation framework, prioritizing investments in strategic growth pillars while returning excess capital to shareholders through its robust share repurchase and dividend programs.' This signals that organic reinvestment and strategic M&A are the primary use of cash, with buybacks and dividends deployed on an opportunistic or formulaic basis from remaining available capital.

MCK 8-K Filed 2026-08-05 Execution disclosure

McKesson completes $2.5B share repurchases in Q1, including $2.25B ASR

Healthcare distributor executed accelerated share repurchase program in May 2026, reducing diluted share count by 5% year-over-year.

MechanismAccelerated Share Repurchase (

What the filing says

McKesson Corporation completed $2.5 billion in common stock repurchases during the first quarter of fiscal 2027 ended June 30, 2026, with $2.25 billion executed under an accelerated share repurchase (ASR) program in May 2026. The repurchases were part of McKesson's broader capital allocation strategy that returned $2.6 billion to shareholders in the quarter, also including $102 million in dividend payments.

The company's diluted share count declined 5% year-over-year to 119.2 million shares outstanding in Q1 FY27, compared to 125.5 million in the prior-year period. This reduction contributed to adjusted earnings per diluted share growth of 20%, reaching $9.93, despite negative free cash flow of $372 million in the quarter driven by working capital dynamics.

McKesson's capital deployment reflects disciplined execution under its stated framework of prioritizing strategic growth investments while returning excess capital to shareholders. On July 21, 2026, the company's Board also approved a 15% increase to the quarterly dividend to $0.94 per share, marking the tenth consecutive year of dividend increases. The ASR mechanism allowed the company to complete a significant repurchase tranch quickly during the quarter rather than executing open-market purchases over an extended period.

McKesson returned $2.6 billion to shareholders, including $2.25 billion through the May 2026 accelerated share repurchase program. — MCKESSON CORP 8-K filing · View on SEC EDGAR →

What this means

McKesson's execution of a $2.25 billion ASR in May 2026, paired with an additional $250 million in open-market repurchases, demonstrates active capital deployment during the quarter. The 5% year-over-year reduction in diluted shares outstanding contributed meaningfully to the 20% adjusted EPS growth rate, illustrating how share count accretion amplifies per-share earnings when underlying net income grows. The filing does not disclose the authorization amount or remaining authorization capacity for this buyback program, nor does it specify the average price paid per share. The negative free cash flow of $372 million in the quarter reflects seasonal working capital needs typical in McKesson's pharmaceutical distribution business, yet the company maintained its buyback and dividend commitments.

Frequently asked questions

What is an accelerated share repurchase (ASR) and why did McKesson use it?: An ASR is a structured transaction in which a company buys a large block of its own shares from an investment bank upfront, with final settlement occurring weeks or months later. McKesson used the ASR mechanism to efficiently execute $2.25 billion of repurchases in May 2026, enabling rapid deployment of capital without prolonging the buyback over many months under standard Rule 10b-18 open-market purchases.
How much did McKesson repurchase in total during Q1 FY27?: McKesson repurchased $2.5 billion of common stock, consisting of $2.25 billion under the May 2026 ASR and approximately $250 million through other means (likely open-market purchases). This was part of a broader $2.6 billion shareholder return that also included $102 million in dividend payments.
Did the buyback materially affect McKesson's earnings per share in Q1?: Yes. Adjusted EPS grew 20% to $9.93 in Q1 FY27 from $8.26 in the prior year. The filing explicitly states that this growth was 'driven by strong operational growth, led by the North American Pharmaceutical and Oncology & Multispecialty segments, and a lower share count,' indicating the 5% year-over-year reduction in diluted shares contributed directly to the EPS accretion.
What is the authorization amount and remaining capacity for this buyback program?: The filing does not disclose the authorization amount or remaining authorization capacity. This is a quarterly earnings release reporting on share repurchases already executed, not an announcement of a new or amended buyback program authorization.
What was the average price paid per share in the Q1 repurchases?: The filing does not disclose the average price paid per share for either the ASR or the total $2.5 billion in repurchases. Only the aggregate dollar amount and the mechanism (ASR plus other repurchases) are specified in the earnings release.
How does McKesson prioritize buybacks relative to other capital allocation?: McKesson states it follows a 'disciplined capital allocation framework, prioritizing investments in strategic growth pillars while returning excess capital to shareholders through its robust share repurchase and dividend programs.' This signals that organic reinvestment and strategic M&A are the primary use of cash, with buybacks and dividends deployed on an opportunistic or formulaic basis from remaining available capital.

execution accelerated-share-repurchase healthcare asr capital-allocation healthcare-services

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.